Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Receivables (2018 - 2026)

Exagen filings provide 9 years of Receivables readings, the most recent being $15.8 million for Q1 2026.

  • On a quarterly basis, Receivables rose 7.48% to $15.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $15.8 million, a 7.48% increase, with the full-year FY2025 number at $10.9 million, up 38.54% from a year prior.
  • Receivables hit $15.8 million in Q1 2026 for Exagen, up from $10.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $17.0 million in Q3 2023 to a low of $6.1 million in Q4 2022.
  • Median Receivables over the past 5 years was $10.9 million (2024), compared with a mean of $11.3 million.
  • Biggest five-year swings in Receivables: skyrocketed 86.29% in 2023 and later crashed 44.92% in 2024.
  • Exagen's Receivables stood at $6.1 million in 2022, then grew by 8.2% to $6.6 million in 2023, then rose by 18.71% to $7.8 million in 2024, then skyrocketed by 38.54% to $10.9 million in 2025, then skyrocketed by 45.56% to $15.8 million in 2026.
  • The last three reported values for Receivables were $15.8 million (Q1 2026), $10.9 million (Q4 2025), and $11.1 million (Q3 2025) per Business Quant data.